Healthcare ❯ Cancer Treatment

Immunotherapy

Clinical Trials CAR-T Cell Therapy FDA Regulations mRNA Technology Immune Checkpoint Inhibitors mRNA-based Therapies T-cell Engineering Vaccine Development Personalized Medicine Antibody Therapy Patient Support T-Cells Advanced Melanoma Monoclonal Antibodies

Personalized mRNA Vaccine Halves Five‑Year Melanoma Recurrence Risk

Five‑year results show durable drops in metastasis with higher survival, leaving phase 3 confirmation plus manufacturing scale‑up as remaining needs.

Securities Class Action Filed Against ImmunityBio After FDA Flags Anktiva Marketing

FDA Accepts Replimune’s Resubmitted RP1 Melanoma Filing, Sets April 2026 Decision

AACR’s 2025 Report Shows Cancer Survival Gains as Early-Onset Cases Climb, Presses for Sustained U.S. Funding

AI Model MSI-SEER Validated Across Diverse Cancer Cohorts and Prepares for Prospective Trials